|
1.
|
|
12 p, 608.0 KB |
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk
/
Gatell, José Mª (Hospital Clínic i Provincial de Barcelona) ;
Assoumou, Lambert (UPMC Univ Paris 06) ;
Moyle, Graeme (St Chelsea and Westminster Hospital) ;
Waters, Laura (Mortimer Market Center) ;
Johnson, Margaret (Royal Free Hospital) ;
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ;
Fox, Julie (Guys and St. Thomas Hospital) ;
Martinez, Esteban (Hospital Clínic i Provincial de Barcelona) ;
Stellbrink, Hans-Jürgen (ICH Study Centrum) ;
Guaraldi, Giovanni (University of Modena and Reggio Emilia) ;
Masia, Mar (Hospital General Universitario de Elche) ;
Gompels, Marl (Southmead Hospital) ;
De Wit, Stephane (Université Libre de Bruxelles) ;
Florence, Eric (Institute of Tropical Medicine) ;
Esser, Stefan (Universitatsklinikum) ;
Raffi, François (CHU de Nantes) ;
Pozniak, Anton L. (St Chelsea and Westminster Hospital) ;
Universitat Autònoma de Barcelona
To compare the efficacy, safety, and impact on lipid fractions of switching from a ritonavir-boosted protease inhibitor (PI/r) to a dolutegravir (DTG) regimen. HIV type 1-infected adults more than 50 years or with a Framingham score more than 10% were eligible if plasma HIV RNA less than 50 copies per ml for at least 24 weeks while on a PI/r regimen. [...]
2017 -  10.1097/QAD.0000000000001675
AIDS, Vol. 31 Núm. 18 (28 2017) , p. 2503-2514
|
|
|
2.
|
|
|
3.
|
|
5 p, 609.6 KB |
XLIMus drug eluting stent : A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial
/
Testa, Luca (IRCCS Policlinico S. Donato) ;
Pero, Gaetano (IRCCS Policlinico S. Donato) ;
Bollati, Mario (IRCCS Policlinico S. Donato) ;
Matteo, Casenghi (IRCCS Policlinico S. Donato) ;
Popolo Rubbio, Antonio (IRCCS Policlinico S. Donato) ;
Cuman, Magdalena (IRCCS Policlinico S. Donato) ;
Moreno, Raul (Hospital Universitario La Paz (Madrid)) ;
Serra, Antoni (Institut d'Investigació Biomèdica Sant Pau) ;
Gomez, Josep Antoni (Hospital Universitari de Bellvitge) ;
Bedogni, Francesco (IRCCS Policlinico S. Donato) ;
Universitat Autònoma de Barcelona
Thin strut 3rd generation drug eluting stents offer the potential advantage over the previous generation of better technical performance and reduced neointimal proliferation parameters, which are linked to mid and late term device failure. [...]
2019 - 10.1016/j.ijcha.2019.100363
International journal of cardiology. Heart & vasculature, Vol. 23 (june 2019) , p. 100363
|
|
|
4.
|
|
18 p, 851.1 KB |
Clinical outcome measures in dementia with Lewy bodies trials : critique and recommendations
/
Rodriguez-Porcel, Federico (Medical University of South Carolina) ;
Wyman-Chick, Kathryn A. (HealthPartners) ;
Abdelnour, Carla (Universitat Autònoma de Barcelona) ;
Toledo, Jon B. (University of Florida) ;
Ferreira, Daniel (Mayo Clinic) ;
Urwyler, Prabitha (University of Bern) ;
Weil, Rimona S. (University College London) ;
Kane, Joseph (Queen's University) ;
Pilotto, Andrea (University of Brescia) ;
Rongve, Arvid (The University of Bergen) ;
Boeve, Bradley (Mayo Clinic) ;
Taylor, John-Paul (Newcastle University) ;
McKeith, Ian (Newcastle University) ;
Aarsland, Dag (King's College London) ;
Lewis, Simon J. G. (University of Sydney)
The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer's or Parkinson's disease. [...]
2022 - 10.1186/s40035-022-00299-w
Translational Neurodegeneration, Vol. 11 (may 2022)
|
|
|
5.
|
|
1 p, 574.4 KB |
Correction : Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations
/
Rodriguez-Porcel, Federico (Medical University of South Carolina) ;
Wyman-Chick, Kathryn A. (HealthPartners) ;
Abdelnour, Carla (Universitat Autònoma de Barcelona) ;
Toledo, Jon B. (University of Florida) ;
Ferreira, Daniel (Mayo Clinic) ;
Urwyler, Prabitha (University of Bern) ;
Weil, Rimona S. (University College London) ;
Kane, Joseph (Queen's University) ;
Pilotto, Andrea (University of Brescia) ;
Rongve, Arvid (The University of Bergen) ;
Boeve, Bradley (Mayo Clinic) ;
Taylor, John-Paul (Newcastle University) ;
McKeith, Ian (Newcastle University) ;
Aarsland, Dag (King's College London) ;
Lewis, Simon J. G. (University of Sydney)
The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer's or Parkinson's disease. [...]
2022 - 10.1186/s40035-022-00306-0
Translational Neurodegeneration, Vol. 11 (may 2022)
|
|
|
6.
|
|
11 p, 529.4 KB |
Nivolumab and sunitinib combination in advanced soft tissue sarcomas : A multicenter, single-arm, phase Ib/II trial
/
Martin-Broto, J. (Universidad de Sevilla) ;
Hindi, Nadia (Universidad de Sevilla) ;
Grignani, G. (Candiolo Cancer Institute) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Redondo, A. (Hospital Universitario La Paz (Madrid)) ;
Valverde, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Stacchiotti, S. (Istituto Nazionale Tumori) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
D'Ambrosio, L. (Candiolo Cancer Institute) ;
Gutierrez, A. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Perez-Vega, H. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Encinas-Tobajas, V. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
De Álava, Enrique (Universidad de Sevilla) ;
Collini, Paola (Istituto Nazionale Tumori) ;
Peña-Chilet, M. (Hospital Virgen Del Rocio) ;
Dopazo, J. (Hospital Virgen Del Rocío) ;
Carrasco-Garcia, I. (Universidad de Sevilla) ;
Lopez-Alvarez, M. (Universidad de Sevilla) ;
Moura, D.S. (Universidad de Sevilla) ;
Lopez-Martin, Jose A (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Universitat Autònoma de Barcelona
Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. [...]
2020 - 10.1136/jitc-2020-001561
Journal for immunotherapy of cancer, Vol. 8 Núm. 2 (17 2020) , p. e001561
|
|
|
7.
|
|
8 p, 514.2 KB |
Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia : Study protocol for the SAFO trial
/
Grillo, Sara (Institut d'Investigació Biomèdica de Bellvitge) ;
Cuervo, Guillermo (Institut d'Investigació Biomèdica de Bellvitge) ;
Carratalà, Jordi (Hospital Universitari de Bellvitge) ;
San-Juan, R (Instituto de Investigación Sanitaria Hospital 12 de Octubre (Madrid)) ;
Aguado, José María (Universidad Complutense de Madrid) ;
Morata, Laura (Hospital Clínic i Provincial de Barcelona) ;
Gómez-Zorrilla, Silvia (Hospital del Mar (Barcelona, Catalunya)) ;
López-Contreras, Joaquín (Institut d'Investigació Biomèdica Sant Pau) ;
Gasch Blasi, Oriol (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Gomila, Aina (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Iftimie, S. (Hospital Universitari Sant Joan de Reus (Tarragona)) ;
García-Pardo, Graciano (Hospital Universitari Joan XXIII de Tarragona) ;
Calbo Sebastián, Esther (Fundació per la Docència i Recerca MútuaTerrassa) ;
Boix-Palop, Lucía (Fundació per la Docència i Recerca MútuaTerrassa) ;
Oriol, I. (Hospital de Sant Joan Despi Moises Broggi) ;
Jover-Sáenz, A. (Institut de Recerca Biomèdica de Lleida) ;
López-Cortés, L.E. (Instituto de Biomedicina de Sevilla) ;
Euba, G. (Instituto de Investigación Sanitaria Biocruces Bizkaia) ;
Aguirregabiria, M. (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Garcia-Pais, M.J. (Instituto de Investigación Sanitaria de Santiago (IDIS)) ;
Gioia, F. (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Paño, J.R. (Instituto de Investigación Sanitaria de Aragón) ;
Pedro-Botet, Maria Luisa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Benítez Díaz, Rosa María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Pérez-Rodríguez, M.T. (Hospital Álvaro Cunqueiro (Vigo)) ;
Meije, Y. (Societat Cooperativa d'Instal·lacions Assistencials Sanitàries) ;
Loeches-Yagüe, M.B. (Hospital Universitario La Paz (Madrid)) ;
Horna, Gertrudis (Institut d'Investigació Biomèdica de Bellvitge) ;
Berbel, Dàmaris (Institut d'Investigació Biomèdica de Bellvitge) ;
Domínguez, Maria Ángeles (Institut d'Investigació Biomèdica de Bellvitge) ;
Padullés, Ariadna (Institut d'Investigació Biomèdica de Bellvitge) ;
Cobollés, Sara (Institut d'Investigació Biomèdica de Bellvitge) ;
Hereu, Pilar (Institut d'Investigació Biomèdica de Bellvitge) ;
Videla, Sebastián (Institut d'Investigació Biomèdica de Bellvitge) ;
Tebé, Cristian (Institut d'Investigació Biomèdica de Bellvitge) ;
Pallarés, Natàlia (Institut d'Investigació Biomèdica de Bellvitge) ;
Miro, Josep M. (Hospital Clínic i Provincial de Barcelona) ;
Pujol, Miquel (Institut d'Investigació Biomèdica de Bellvitge) ;
Universitat Autònoma de Barcelona
Methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia is a frequent condition, with high mortality rates. There is a growing interest in identifying new therapeutic regimens able to reduce therapeutic failure and mortality observed with the standard of care of beta-lactam monotherapy. [...]
2021 - 10.1136/bmjopen-2021-051208
BMJ open, Vol. 11 Núm. 8 (may 2021) , p. e051208
|
|
|
8.
|
|
12 p, 2.9 MB |
Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1) : Refining muscle involvement and implications for clinical trials
/
Garibaldi, Matteo (Sant'Andrea Hospital) ;
Nicoletti, Tommaso (Università Cattolica del Sacro Cuore) ;
Bucci, Elisabetta (Sant'Andrea Hospital) ;
Fionda, Laura (Sant'Andrea Hospital. Sapienza University of Rome) ;
Leonardi, Luca (Sant'Andrea Hospital) ;
Morino, Stefania (Sant'Andrea Hospital) ;
Tufano, Laura (Sant'Andrea Hospital) ;
Alfieri, Girolamo (Sant'Andrea Hospital) ;
Lauletta, Antonio (Sant'Andrea Hospital) ;
Merlonghi, Gioia (Sant'Andrea Hospital) ;
Perna, Alessia (Università Cattolica del Sacro Cuore) ;
Rossi, Salvatore (Università Cattolica del Sacro Cuore) ;
Ricci, Enzo (Università Cattolica del Sacro Cuore) ;
Alonso-Pérez, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Tartaglione, Tommaso (Istituto Dermopatico dell'Immacolata) ;
Petrucci, Antonio (San Camillo Forlanini Hospital) ;
Pennisi, Elena Maria (San Filippo Neri Hospital) ;
Salvetti, Marco (IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed) ;
Cutter, Gary (University of Alabama at Birmingham) ;
Diaz-Manera, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Silvestri, Gabriella (Università Cattolica del Sacro Cuore) ;
Antonini, Giovanni (Sant'Andrea Hospital)
Only a few studies have reported muscle imaging data on small cohorts of patients with myotonic dystrophy type 1 (DM1). We aimed to investigate the muscle involvement in a large cohort of patients in order to refine the pattern of muscle involvement, to better understand the pathophysiological mechanisms of muscle weakness, and to identify potential imaging biomarkers for disease activity and severity. [...]
2021 - 10.1111/ene.15174
European Journal of Neurology, Vol. 29 (december 2021) , p. 843-854
|
|
|
9.
|
|
8 p, 275.5 KB |
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
/
Aimo, Alberto (Fondazione Toscana Gabriele Monasterio) ;
Spitaleri, Giosafat (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Nieri, Dario (Pisa University Hospital) ;
Tavanti, Laura Maria (Pisa University Hospital) ;
Meschi, Claudia (University of Pisa) ;
Panichella, Giorgia (Scuola Superiore Sant'Anna) ;
Lupón, Josep (Instituto de Salud Carlos III) ;
Pistelli, Francesco (Pisa University Hospital) ;
Carrozzi, Laura (University of Pisa) ;
Bayés-Genís, Antoni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Emdin, Michele (Fondazione Toscana Gabriele Monasterio) ;
Universitat Autònoma de Barcelona
Pirfenidone (PFD) slows the progression of idiopathic pulmonary fibrosis (IPF) by inhibiting the exaggerated fibrotic response and possibly through additional mechanisms, such as anti-inflammatory effects. [...]
2022 - 10.15420/cfr.2021.30
Cardiac Failure Review, Vol. 8 (april 2022)
|
|
|
10.
|
|
10 p, 683.9 KB |
Ozanimod in relapsing multiple sclerosis : Pooled safety results from the clinical development program
/
Selmaj, Krzysztof W. (University of Warmia and Mazury) ;
Cohen, Jeffrey A. (Neurological Institute) ;
Comi, Giancarlo (Vita-Salute San Raffaele University) ;
Bar-Or, Amit (University of Pennsylvania) ;
Arnold, Douglas Lorne (McGill University) ;
Steinman, Lawrence (Stanford University Medical Center) ;
Hartung, Hans-Peter (Medical University Vienna) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Kubala Havrdova, Eva (Charles University) ;
Cree, Bruce A. C (UCSF University of California San Francisco) ;
Minton, Neil (Bristol Myers Squibb) ;
Sheffield, James K. (Bristol Myers Squibb) ;
Ding, Ning (Bristol Myers Squibb) ;
Kappos, Ludwig (University of Basel) ;
Universitat Autònoma de Barcelona
Background: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for the treatment of relapsing multiple sclerosis (RMS). In phase 3 trials, ozanimod was well tolerated and superior to interferon beta-1a 30 µg once-weekly in reducing clinical and radiologic disease activity. [...]
2021 - 10.1016/j.msard.2021.102844
Multiple Sclerosis and Related Disorders, Vol. 51 (june 2021) , p. 102844
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
